K-Dur generic
Executive Summary
Schering has settled patent litigation regarding generic potassium chloride with Upsher-Smith, the company reports in its Nov. 13 10-Q. Schering also settled with ESI Lederle; the agreements are under FTC investigation (1"The Pink Sheet" April 3, p. 6)
You may also be interested in...
Schering K-Dur Settlement With AHP Under Investigation By FTC
A settlement between Schering-Plough and ESI Lederle regarding patent litigation surrounding Schering's K-Dur is among cases being investigated by the Federal Trade Commission for potential antitrust violations.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials